HRP20130852T1 - Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component - Google Patents

Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component

Info

Publication number
HRP20130852T1
HRP20130852T1 HRP20130852TT HRP20130852T HRP20130852T1 HR P20130852 T1 HRP20130852 T1 HR P20130852T1 HR P20130852T T HRP20130852T T HR P20130852TT HR P20130852 T HRP20130852 T HR P20130852T HR P20130852 T1 HRP20130852 T1 HR P20130852T1
Authority
HR
Croatia
Prior art keywords
methods
treatment
therapeutic agents
autoimmune
signaling
Prior art date
Application number
HRP20130852TT
Other languages
Croatian (hr)
Inventor
Sharon Lea Aukerman
Bahija Jallal
Mohammad Luqman
Original Assignee
Novartis Ag
Xoma Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Xoma Technology Ltd. filed Critical Novartis Ag
Publication of HRP20130852T1 publication Critical patent/HRP20130852T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)

Abstract

Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
HRP20130852TT 2005-05-18 2013-09-11 Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component HRP20130852T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68257505P 2005-05-18 2005-05-18
US74933605P 2005-12-09 2005-12-09
PCT/US2006/019325 WO2006125117A2 (en) 2005-05-18 2006-05-18 Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component

Publications (1)

Publication Number Publication Date
HRP20130852T1 true HRP20130852T1 (en) 2013-10-25

Family

ID=36968724

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130852TT HRP20130852T1 (en) 2005-05-18 2013-09-11 Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component

Country Status (12)

Country Link
US (1) US8333970B2 (en)
EP (2) EP2312315A1 (en)
JP (1) JP5421590B2 (en)
AU (1) AU2006247134B2 (en)
CA (1) CA2608750A1 (en)
DK (1) DK1889065T3 (en)
ES (1) ES2429564T3 (en)
HK (1) HK1110942A1 (en)
HR (1) HRP20130852T1 (en)
PL (1) PL1889065T3 (en)
PT (1) PT1889065E (en)
WO (1) WO2006125117A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563584B2 (en) 2001-07-10 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
KR101317235B1 (en) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 Antagonist anti-cd40 antibody pharmaceutical compositions
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
CA2704499C (en) 2007-11-07 2020-03-10 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
BRPI0906858B8 (en) 2008-01-18 2021-07-27 Harvard College in vitro methods to detect the presence of a cancer cell in an individual and to identify a specific tumor signature in an individual having cancer.
EP2352998A4 (en) 2008-11-07 2011-09-21 Centocor Ortho Biotech Inc Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP2384367A4 (en) * 2008-12-30 2013-07-10 Janssen Biotech Inc Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis
JP5302054B2 (en) * 2009-03-06 2013-10-02 オリンパス株式会社 Method for detecting apoptotic cells fragmented with DNA, cell image analyzer, and program
JP5836929B2 (en) * 2009-04-18 2015-12-24 ジェネンテック， インコーポレイテッド Method for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibody
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
JP2013520208A (en) * 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ Diagnosis, prognosis and treatment of autoimmune diseases
EP2566973A4 (en) * 2010-05-04 2013-11-27 Medimmune Llc Optimized degenerative muscle disease diagnostics and treatments
US20120053073A1 (en) 2010-07-23 2012-03-01 President And Fellows Of Harvard College Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
BR112013001752A2 (en) 2010-07-23 2016-05-31 Harvard College method of detecting disease or condition using phagocytic cells
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
US20120196762A1 (en) * 2011-01-27 2012-08-02 Paradis Norman A Method and apparatus for discovery, development and clinical application of multiplex assays based on patterns of cellular response
CN106928362B (en) 2011-04-29 2021-10-26 埃派斯进有限公司 anti-CD 40 antibodies and methods of use thereof
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014042981A2 (en) * 2012-09-17 2014-03-20 Digital Therapeutics Llc Treating digital ulcers, hypertension, vasculitis conditions, or inflammatory myositis conditions
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
TWI502199B (en) * 2013-05-23 2015-10-01 Univ Nat Central Use of tumor necrosis factor (tnf) receptor-associated factor 7 (traf7) as biomarkers for systemic lupus erythematosus (sle), method and kit for detecting of human with sle
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
ES2885476T3 (en) * 2015-10-05 2021-12-13 Ucb Biopharma Sprl Molecular signatures for use in diagnosis and analysis of response to treatment of autoimmune diseases
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
CN112638375A (en) 2018-06-15 2021-04-09 旗舰创业创新五公司 Increasing immune activity through modulation of post-cellular signaling factors
KR20210027436A (en) * 2018-06-29 2021-03-10 베링거 인겔하임 인터내셔날 게엠베하 Anti-CD40 antibodies for use in treating autoimmune diseases
WO2020102721A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als)
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
BR112021021923A2 (en) * 2019-05-08 2022-02-22 Novartis Ag Anti-cd40 antibodies for use in the treatment of dm1 and insulitis
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4256087A1 (en) * 2020-12-02 2023-10-11 Albert Einstein College of Medicine Method for predicting patient response to cd40-targeted therapies
CN112860824B (en) * 2021-01-15 2021-12-10 中国科学院沈阳应用生态研究所 Scale adaptability evaluation method for high-resolution DEM terrain feature extraction
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023230538A2 (en) * 2022-05-27 2023-11-30 Eledon Pharmaceuticals, Inc. Methods for the treatment of amyotrophic lateral sclerosis
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JP3190042B2 (en) 1991-10-31 2001-07-16 マトリテク インコーポレイテッド Nuclear matrix protein solution assay
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US20020086321A1 (en) 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
CN100341896C (en) 1993-09-02 2007-10-10 达特茅斯学院理事 Anti-GP39 antibodies and uses therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JPH09507074A (en) 1993-12-23 1997-07-15 イミュネックス・コーポレーション Method for preventing or treating a disease characterized by tumor cells expressing CD40
JPH09510088A (en) 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク Final complement inhibitor fusion gene and protein
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
GB9601108D0 (en) 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US6579692B1 (en) 1996-03-06 2003-06-17 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
WO1998022589A2 (en) 1996-11-20 1998-05-28 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DE69833755T2 (en) 1997-05-21 2006-12-28 Biovation Ltd. METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS
JP2002504910A (en) 1997-06-20 2002-02-12 バイオジェン，インコーポレイテッド CD154 blocking therapy for therapeutic protein inhibitor syndrome
DE69829402T2 (en) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara EXPRESSION PROFILES IN ADULTS AND FOLDS ORGANS
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO1999059578A1 (en) * 1998-05-19 1999-11-25 Research Development Foundation Triterpene compositions and methods for use thereof
CN1202128C (en) 1998-12-08 2005-05-18 拜奥威神有限公司 Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
IL144952A0 (en) 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU5914201A (en) 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
EP1399435A2 (en) 2000-09-01 2004-03-24 Biogen, Inc. Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications
AU2001296507A1 (en) * 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
DK1391464T3 (en) 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoclonal antibody
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006517916A (en) * 2002-10-30 2006-08-03 ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド Methods for treating and preventing apoptosis-related diseases using RNA interference substances
GB0301566D0 (en) * 2003-01-23 2003-02-26 Eirx Therapeutics Ltd Kinasaes and GPCRs involved in apoptosis
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use

Also Published As

Publication number Publication date
US20080274118A1 (en) 2008-11-06
CA2608750A1 (en) 2006-11-23
PT1889065E (en) 2013-09-27
DK1889065T3 (en) 2013-09-02
WO2006125117A3 (en) 2007-01-18
EP1889065B1 (en) 2013-07-10
US8333970B2 (en) 2012-12-18
ES2429564T3 (en) 2013-11-15
EP2312315A1 (en) 2011-04-20
AU2006247134B2 (en) 2012-05-10
PL1889065T3 (en) 2013-12-31
AU2006247134A1 (en) 2006-11-23
HK1110942A1 (en) 2008-07-25
JP5421590B2 (en) 2014-02-19
WO2006125117A2 (en) 2006-11-23
EP1889065A2 (en) 2008-02-20
JP2008539791A (en) 2008-11-20

Similar Documents

Publication Publication Date Title
HRP20130852T1 (en) Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2006125143A3 (en) Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2007061755A3 (en) Systems and methods to assess one or more body fluid metrics
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
ECSP10010007A (en) TREATMENT WITH LIGANDOS ALPHA-7-SELECTIVOS
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
EP2617837A3 (en) Biomarkers for predicting anti-TNF responsiveness or non-responsiveness
GB0524110D0 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
DK1719507T3 (en) Beta-2 adrenoceptor agonists for the treatment of connective tissue disorders of the skin
WO2006083937A3 (en) Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
MX2007013834A (en) Vascular disease therapies.
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
WO2005118592A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB0625523D0 (en) In vivo imaging agents
MA33839B1 (en) Combinations and methods of diagnosis and treatment of tumors
NO20071613L (en) Compounds for myocardial perfusion imaging
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
EP1870710A4 (en) Biomarker for diagnosing heart disease and the use thereof
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2006102521A3 (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1899726A4 (en) Methods for diagnosing and treating cerebrovascular events based on nr2 peptides
WO2006023891A3 (en) Ligand-dependant activation of nur77 and uses thereof